Opyl Limited Streamlines with Trial Screen Transition
Opyl Ltd. (AU:OPL) has released an update.
Opyl Limited has announced that Opin has been successfully rebranded as Trial Screen following its acquisition by Dr. Hugo Stephenson, who plans to invest $1.2 million into the business. Opyl will retain a 20% stake in Trial Screen, allowing it to focus on growing its TrialKey product and improving its financial position to target high-growth areas in clinical trials and medical research.
For further insights into AU:OPL stock, check out TipRanks’ Stock Analysis page.
TipRanks is the most comprehensive data set of sell side analysts and hedge fund managers. TipRanks' multi-award winning platform ranks financial experts based on measured performance and the accuracy of their predictions so investors know who to trust when making investment decisions.